Howard Hughes (HHH) remains a 'Hold' as strategic risks and execution concerns outweigh apparent valuation discounts. Pershing/Ackman's insurance pivot, highlighted by the $2B+ Vantage deal, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results